Form 8-K - Current report:
SEC Accession No. 0001367644-25-000188
Filing Date
2025-09-11
Accepted
2025-09-11 16:07:36
Documents
15
Period of Report
2025-09-05
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ebs-20250905.htm   iXBRL 8-K 29917
2 EX-99.1 a09092025acam2000pressrele.htm EX-99.1 18417
7 image2.jpg GRAPHIC 7489
  Complete submission text file 0001367644-25-000188.txt   212711

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ebs-20250905.xsd EX-101.SCH 2059
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ebs-20250905_def.xml EX-101.DEF 15289
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ebs-20250905_lab.xml EX-101.LAB 26963
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ebs-20250905_pre.xml EX-101.PRE 15991
17 EXTRACTED XBRL INSTANCE DOCUMENT ebs-20250905_htm.xml XML 2722
Mailing Address 300 PROFESSIONAL DR GAITHERSBURG MD 20879
Business Address 300 PROFESSIONAL DR GAITHERSBURG MD 20879 240-631-3200
Emergent BioSolutions Inc. (Filer) CIK: 0001367644 (see all company filings)

EIN.: 141902018 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33137 | Film No.: 251308607
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)